Treatment of children with phenylketonuria using a phenylalanine-free protein hydrolysate (Albumaid XP).
Albumaid XP, a phenylalanine-free protein hydrolysate, was used for treatment of five phenylketonuric infants born between January, 1970, and September, 1972. The results were compared with those obtained from the five infants most recently treated with Lofenalac in our clinic prior to 1970. Treatment was begun by 2 months of age in all instances. Satisfactory physical growth and mental development were achieved using either Albumaid XP or Lofenalac, and there were no major differences in the outcomes with either treatment. The two protein sources may be used interchangeably for treatment of phenylketonuria.
D000596:Amino Acids / Q000097:blood; D001827:Body Height; D001835:Body Weight; D002657:Child Development; D002675:Child, Preschool; D004734:Energy Metabolism; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010649:Phenylalanine / Q000032:analysis / Q000097:blood; D010661:Phenylketonurias / Q000178:diet therapy*; D011492:Protein Hydrolysates / Q000032:analysis / Q000627:therapeutic use*
D000596:Amino Acids; D011492:Protein Hydrolysates; D010649:Phenylalanine